Warning! GuruFocus detected
1 Medium warning sign
with MCAP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
MedCap AB
ISIN : SE0009160872
Compare
Compare
Traded in other countries / regions
MCAP.SwedenMCAPs.UK61MA.Germany IPO Date
2004-06-23Description
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.03 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | 0.9 | |||||
| Interest Coverage | 13.16 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 6.66 | |||||
| Beneish M-Score | -2.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 25.3 | |||||
| 3-Year EBITDA Growth Rate | 25.1 | |||||
| 3-Year EPS without NRI Growth Rate | 35.4 | |||||
| 3-Year FCF Growth Rate | 74.3 | |||||
| 3-Year Book Growth Rate | 22.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 16.77 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.63 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 93.22 | |||||
| 9-Day RSI | 81 | |||||
| 14-Day RSI | 70.76 | |||||
| 3-1 Month Momentum % | -2.31 | |||||
| 6-1 Month Momentum % | -32.33 | |||||
| 12-1 Month Momentum % | -12.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | |||||
| Quick Ratio | 1.96 | |||||
| Cash Ratio | 1.12 | |||||
| Days Inventory | 133.62 | |||||
| Days Sales Outstanding | 57.13 | |||||
| Days Payable | 106.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | -1.45 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.52 | |||||
| Operating Margin % | 15.08 | |||||
| Net Margin % | 11.48 | |||||
| FCF Margin % | 16.26 | |||||
| ROE % | 18.06 | |||||
| ROA % | 11.25 | |||||
| ROIC % | 16.59 | |||||
| 3-Year ROIIC % | 33.11 | |||||
| ROC (Joel Greenblatt) % | 44.96 | |||||
| ROCE % | 18.89 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.06 | |||||
| Forward PE Ratio | 28.75 | |||||
| PE Ratio without NRI | 29.06 | |||||
| Shiller PE Ratio | 68.78 | |||||
| Price-to-Owner-Earnings | 16.11 | |||||
| PEG Ratio | 1.27 | |||||
| PS Ratio | 3.33 | |||||
| PB Ratio | 4.72 | |||||
| Price-to-Tangible-Book | 10.12 | |||||
| Price-to-Free-Cash-Flow | 20.51 | |||||
| Price-to-Operating-Cash-Flow | 16.73 | |||||
| EV-to-EBIT | 22.03 | |||||
| EV-to-EBITDA | 15.64 | |||||
| EV-to-Revenue | 3.44 | |||||
| EV-to-FCF | 19.64 | |||||
| Price-to-GF-Value | 0.99 | |||||
| Price-to-Projected-FCF | 2.19 | |||||
| Price-to-Median-PS-Value | 1.33 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.2 | |||||
| Price-to-Graham-Number | 3.67 | |||||
| Price-to-Net-Current-Asset-Value | 29.91 | |||||
| Earnings Yield (Greenblatt) % | 4.53 | |||||
| FCF Yield % | 4.72 | |||||
| Forward Rate of Return (Yacktman) % | 22.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MedCap AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 1,806.6 | ||
| EPS (TTM) (kr) | 13.9 | ||
| Beta | 0.01 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 1.03 | ||
| Volatility % | 55.1 | ||
| 14-Day RSI | 70.76 | ||
| 14-Day ATR (kr) | 14.17353 | ||
| 20-Day SMA (kr) | 372.65 | ||
| 12-1 Month Momentum % | -12.73 | ||
| 52-Week Range (kr) | 329 - 632 | ||
| Shares Outstanding (Mil) | 14.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MedCap AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MedCap AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
MedCap AB Frequently Asked Questions
What is MedCap AB(OSTO:MCAP)'s stock price today?
The current price of OSTO:MCAP is kr415.50. The 52 week high of OSTO:MCAP is kr632.00 and 52 week low is kr329.00.
When is next earnings date of MedCap AB(OSTO:MCAP)?
The next earnings date of MedCap AB(OSTO:MCAP) is 2025-04-29.
Does MedCap AB(OSTO:MCAP) pay dividends? If so, how much?
MedCap AB(OSTO:MCAP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers